Evidence map›Paper›PMID 39240809›Full record

ArticlePloS one2024

hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560.

Kieran W Benn, Patrick H Yuan, Harvey K Chong, Stanley S Stylii, Rodney B Luwor, Christopher R French

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Kieran W BennNeural Dynamics Laboratory, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0009-0008-4673-9093
Patrick H YuanNeural Dynamics Laboratory, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Harvey K ChongNeural Dynamics Laboratory, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
Stanley S StyliiDepartment of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
Rodney B LuworDepartment of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
Christopher R FrenchNeural Dynamics Laboratory, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-0628-596X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are highly malignant brain tumours that remain refractory to treatment. Treatment is typically surgical intervention followed by concomitant temozolomide and radiotherapy; however patient prognosis remains poor. Voltage gated ion channels have emerged as novel targets in cancer therapy and inhibition of a potassium selective subtype (hERG, Kv11.1) has demonstrated antitumour activity. Unfortunately blockade of hERG has been limited by cardiotoxicity, however hERG channel agonists have produced similar chemotherapeutic benefit without significant side effects. In this study, electrophysiological recordings suggest the presence of hERG channels in the anaplastic astrocytoma cell line SMA-560, and treatment with the hERG channel agonist NS1643, resulted in a significant reduction in the proliferation of SMA-560 cells. In addition, NS1643 treatment also resulted in a reduction of the secretion of matrix metalloproteinase-9 and SMA-560 cell migration. When combined with temozolomide, an additive impact was observed, suggesting that NS1643 may be a suitable adjuvant to temozolomide and limit the invasiveness of glioma.

Indexed as

AstrocytomaCell MovementCell ProliferationEther-A-Go-Go Potassium ChannelsMatrix Metalloproteinase 9TemozolomideAntineoplastic AgentsBrain NeoplasmsCell Line, TumorCresolsDacarbazineERG1 Potassium ChannelHumansNeoplasm InvasivenessPhenylurea Compounds1,3-bis(2-hydroxy-5-trifluoromethylphenyl)ureaAntineoplastic AgentsCresolsDacarbazineERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsKCNH2 protein, humanMatrix Metalloproteinase 9Phenylurea CompoundsTemozolomide

Identifiers

PMID39240809
PMCPMC11379238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.